Blood product use for radiological/nuclear trauma: product development and US regulatory considerations

• Toby A Silverman,
• Annette M Shadiack,
• Kimberly A Hofmeyer,
• Ashley E Cecere,
• Derek L Eisnor,
• Corey M Hoffman,
• Shannon G Loelius,
• Aditiben Patel,
• Mary J Homer

Affiliations

Toby A Silverman

Tunnell Government Services, Bethesda, Maryland, USA

Annette M Shadiack

Tunnell Government Services, Bethesda, Maryland, USA

Kimberly A Hofmeyer

Biomedical Advanced Research and Development Authority, Washington, District of Columbia, USA

Ashley E Cecere

Biomedical Advanced Research and Development Authority, Washington, District of Columbia, USA

Derek L Eisnor

Division of Clinical Development, Biomedical Advanced Research and Development Authority, Washington, District of Columbia, USA

Corey M Hoffman

Division of Chemical, Biological, Radiological, and Nuclear Medical Countermeasure, Biomedical Advanced Research and Development Authority, Washington, District of Columbia, USA

Shannon G Loelius

Division of Chemical, Biological, Radiological, and Nuclear Medical Countermeasure, Biomedical Advanced Research and Development Authority, Washington, District of Columbia, USA

Aditiben Patel

Division of Regulatory and Quality Affairs, Biomedical Advanced Research and Development Authority, Washington, District of Columbia, USA

Mary J Homer

Division of Chemical, Biological, Radiological, and Nuclear Medical Countermeasure, Biomedical Advanced Research and Development Authority, Washington, District of Columbia, USA